This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice.
Research article
Is Serum Vasohibin 1 Level Associated With the Development of Nephropathy in Diabetic Patients?
Orcun Altunoren
Kahramanmaras Sutcu Imam Universitesi
Corresponding Author
ORCiD: https://orcid.org/0000-0002-8913-4341
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Glomerular filtration surface area and glomerular filtration rate (GFR) are increased in patients with diabetic nephropathy, especially in the early phase of the disease. Glomerular neoangiogenesis contributes to this increased GFR. Increased GFR is associated with glomerular neoangiogenesis. Vasohibin-1 is an inhibitor of neoangiogenesis. The aim of this study is to evaluate serum vasohibin-1 levels of diabetic patients with and without diabetic nephropathy (DN).
Methods: One hundred and five diabetic patients and 39 healthy controls matched for age and gender were included in the study. Diabetic patients with eGFR<60 ml/min/1,73m2 and/or those who had persistent proteinuria (>200 mg/gr) measured by urine protein/creatinine ratio (UP/C) were diagnosed as overt diabetic nephropathy (DN) if they haven’t any other known kidney diseases. Serum vasohibin-1 levels were measured by ELISA. Serum creatinine, eGFR, UP/C and vasohibin-1 levels were recorded.
Results: Thirty-four percent of diabetic patients had DN. Systolic blood pressure and UP/C were higher in diabetic patients than healthy controls and age, sex, eGFR were similar. Diabetic patients have nonsignificantly lower serum vasohibin-1 levels than healthy controls. Patients with DN had higher UP/C, lower eGFR and long-standing diabetes compared to diabetic patients without nephropathy. Serum vasohibin-1 levels were similar between diabetic patients with and without DN. There was no correlation between vasohibin-1 levels and eGFR or UP/C.
Conclusions: In this study for the first time we showed that diabetic patients have slightly lower vasohibin-1 levels than healthy subjects but there was no difference between diabetic patients with and without nephropathy in terms of serum vasohibin levels. Because, vasohibin-1 exhibits its anti-angiogenetic properties by acting via autocrine-paracrine pathways; local vasohibin activity at the tissue level may be more important than the circulating levels.
Keywords
Diabetic nephropathy, Proteinuria, Vascular endothelial growth factor-A, Vasohibin-1
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 22 Sep, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Urology & Nephrology
Learn more about our company.
This is a preprint. It has not completed peer review.
Research article
Is Serum Vasohibin 1 Level Associated With the Development of Nephropathy in Diabetic Patients?
Orcun Altunoren
Kahramanmaras Sutcu Imam Universitesi
Corresponding Author
ORCiD: https://orcid.org/0000-0002-8913-4341
Badges
Prescreen
This manuscript passed our Prescreen assessment
Complete author information
Appropriate declaration statements
Potential risks to human health
Prescreen
History
CURRENT STATUS: Posted
Version 1
Posted 22 Sep, 2020
No community comments so far
Metrics
Comments: 0
PDF Downloads: ...
HTML Views: ...
Subject Areas
Urology & Nephrology
License:
This work is licensed under a CC BY 4.0 License. Read Full License
Background: Glomerular filtration surface area and glomerular filtration rate (GFR) are increased in patients with diabetic nephropathy, especially in the early phase of the disease. Glomerular neoangiogenesis contributes to this increased GFR. Increased GFR is associated with glomerular neoangiogenesis. Vasohibin-1 is an inhibitor of neoangiogenesis. The aim of this study is to evaluate serum vasohibin-1 levels of diabetic patients with and without diabetic nephropathy (DN).
Methods: One hundred and five diabetic patients and 39 healthy controls matched for age and gender were included in the study. Diabetic patients with eGFR<60 ml/min/1,73m2 and/or those who had persistent proteinuria (>200 mg/gr) measured by urine protein/creatinine ratio (UP/C) were diagnosed as overt diabetic nephropathy (DN) if they haven’t any other known kidney diseases. Serum vasohibin-1 levels were measured by ELISA. Serum creatinine, eGFR, UP/C and vasohibin-1 levels were recorded.
Results: Thirty-four percent of diabetic patients had DN. Systolic blood pressure and UP/C were higher in diabetic patients than healthy controls and age, sex, eGFR were similar. Diabetic patients have nonsignificantly lower serum vasohibin-1 levels than healthy controls. Patients with DN had higher UP/C, lower eGFR and long-standing diabetes compared to diabetic patients without nephropathy. Serum vasohibin-1 levels were similar between diabetic patients with and without DN. There was no correlation between vasohibin-1 levels and eGFR or UP/C.
Conclusions: In this study for the first time we showed that diabetic patients have slightly lower vasohibin-1 levels than healthy subjects but there was no difference between diabetic patients with and without nephropathy in terms of serum vasohibin levels. Because, vasohibin-1 exhibits its anti-angiogenetic properties by acting via autocrine-paracrine pathways; local vasohibin activity at the tissue level may be more important than the circulating levels.